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Background: Obesity is associated with the rise of noncommunicable diseases worldwide. The pathophysiology
behind this disease involves the increase of adipose tissue, being inversely related to adiponectin, but directly
related to insulin resistance and metabolic syndrome (MetS). Therefore, this study aimed to determine the
relationship between adiponectin levels with each component of MetS in eutrophic and obese Mexican children.
Methods: A cross sectional study was conducted in 190 school-age children classified as obese and 196 classified
as eutrophic. Adiponectin, glucose, insulin, high density lipoprotein cholesterol (HDL-C) and triglycerides were
determined from a fasting blood sample. Height, weight, waist circumference, systolic and diastolic blood pressures
(BP) were measured; MetS was evaluated with the IDF definition. The study groups were divided according to
tertiles of adiponectin, using the higher concentration as a reference. Linear regression analysis was used to assess
the association between adiponectin and components of the MetS. Finally, stepwise forward multiple logistic
regression analysis controlling for age, gender, basal HOMA-IR values and BMI was performed to determine the
odds ratio of developing MetS according to adiponectin tertiles.
Results: Anthropometric and metabolic measurements were statistically different between eutrophic and obese
children with and without MetS (P <0.001). The prevalence of MetS in obese populations was 13%. Adiponectin
concentrations were 15.5 ± 6.1, 12.0 ± 4.8, 12.4 ± 4.9 and 9.4 ± 2.8 μg/mL for eutrophic and obese subjects, obese
without MetS, and obese with MetS, respectively (P <0.001). Obese children with low values of adiponectin
exhibited a higher frequency of MetS components: abdominal obesity, 49%; high systolic BP, 3%; high diastolic BP,
2%; impaired fasting glucose, 17%; hypertriglyceridemia, 31%; and low HDL-C values, 42%. Adjusted odds ratio of
presenting MetS according to adiponectin categories was 10.9 (95% CI 2.05; 48.16) when the first tertile was
compared with the third.
Conclusion: In this sample of eutrophic and obese Mexican children we found that adiponectin concentrations
and MetS components have an inversely proportional relationship, which supports the idea that this hormone
could be a biomarker for identifying individuals with risk of developing MetS.
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During the last three decades, obesity has emerged world-
wide as an epidemic affecting all ages and socioeconomic
levels. In Mexico, the prevalence of obesity in school-age
children has an upward trend [1]. The Mexican National
Health and Nutrition Survey 2006 reported an increase of
77% and 47% in boys and girls respectively, between 1999
and 2006 [2].The childhood obesity epidemic has led to a
parallel rise in the prevalence of pediatric forms of chronic
illnesses such as type 2 diabetes (T2D) and high blood
pressure (BP), which in the recent past were typically adult
diseases [3,4].
Despite the fact that the classification of metabolic
syndrome (MetS) has several limitations, for instance
the use of categorical criteria in each of its components
[5,6], it is a useful clinical tool to identify individuals
with risk of developing diseases associated with obesity.
Currently, the pathophysiology behind this syndrome
begins with the fact that the adipose tissue, visceral and
ectopic, functions as an endocrine gland producing an
imbalance between pro and anti-inflammatory cytokines.
Pro-inflammatory cytokines such as TNF-α, IL-6, IL-1β, and
PAI-1, increase; while adiponectin, an anti-inflammatory
cytokine, decreases [7]. This imbalance elicits low-
degree systemic inflammation associated with insulin
resistance [8]. Owing to that after weight reduction,
adiponectin increases, improving insulin sensitivity
throughout the body [9-12], its plasmatic concentration
has been proposed as a candidate biomarker to identify
metabolic alterations including those of MetS [13-15].
However, in children this adiponectin role still remains
controversial [16,17].
Therefore, the aim of this study was to determine the
relationship between plasmatic adiponectin levels and
MetS components in eutrophic and obese children, and
to assess whether this hormone could be a biomarker
for MetS in Mexican children.
Methods
This epidemiological study was conducted from November
2007 to December 2010 in nine middle-class schools of
Mexico City. Prior to the study, ethical clearance was
obtained by both the ethics and research institutional
boards of the Hospital Infantil de México “Federico
Gómez” and school authorities; likewise, written informed
consent was obtained from the participants and their
parents in each of the two stages of the study. The first
stage aimed to identify obese school-age children. For
this purpose and following international anthropomet-
ric guidelines [18], a trained team of nurses measured
children’s weight and height without shoes and wearing
light clothing. Weight was taken using a digital scale
(Seca, Hamburg, Germany) to the nearest 0.1 kg; height
was measured using a Seca 225 stadiometer to thenearest 0.1 cm. This screening was performed in 1,441
children between 6 and 12 years of age, and eutrophic
or obese status was assessed using BMI percentiles
according to the 2000 Centers for Disease Control and
Prevention reference (Atlanta, GA, USA) [19].
Eutrophic status was considered when BMI was be-
tween 25th and 75th percentile and obese when the BMI
was >95th percentile for the child´s age and gender. Be-
cause the purpose of the study was assessing if plasmatic
adiponectin levels categorized in tertiles were able to
identify a certain profile as healthy or at risk, the sample
was designed to have contrasting nutritional status
groups, either normal or obese. In order to fulfill the
study´s aims, individuals between normal and obese
(BMI >75th pc < 95th pc) or between normal and mal-
nourished (BMI < 25th pc) were purposefully excluded.
Of all the participants, 286 were obese (19.9%), 20 of
them did not meet the inclusion criteria and 59 did not
accept to participate. In 190 out of 207 individuals
complete blood samples were collected. According to
our criteria, there were 524 eutrophic children of which
250 were invited to participate and 209 accepted. In 196,
whole blood samples were drawn. Those who self-
reported as having an acute infectious disease, suffering
from chronic illness such as allergies and autoimmune
diseases that could alter cytokines patterns, or those
who were participating in a weight reduction program
were excluded.
In the second stage, BP was obtained by auscultatory
method using a sphygmomanometer (ALPK2, Tokyo,
Japan) with appropriate cuff size for arm length, follow-
ing North American guidelines issued in 2004 [20]. Four
BP readings were taken for each participant on the right
arm in a sitting position, resting 1 minute between each
measurement. The mean of the last three readings was
considered the final level of BP. Waist circumference
(WC) was measured at the midpoint between the lowest
rib and the iliac crest after a normal exhalation with
children in the standing position. A fasting blood sample
was used to determine insulin by chemiluminescence
immunoassay (IMMULITE 2000, Euro, DPC, Llanberis,
UK), glucose, total cholesterol, low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), and triglycerides (ILAB 300, Instrumentation
Laboratory, Barcelona, Spain). Intra and inter assay coef-
ficients of variation (CV) values were <5%. Total adipo-
nectin was determined by ELISA method (Human
Adiponectin ELISA Kit, Millipore, St. Charles, MO, USA),
in which the mean of the minimum detectable concentra-
tion was 0.78 ng/mL. Intra- and inter assay CV were <7.4
and <8.4 %, respectively. All analyses were performed dur-
ing the 2–5 days following the blood sample extraction.
HOMA-IR was obtained by the following equation:
[fasting glucose (mg/dL) x fasting insulin (μU/mL)/405].
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which corresponds to the 90th percentile in a population
of healthy children [21].
Definition of MetS
MetS was defined according to guidelines of the Inter-
national Diabetes Federation (IDF) [22], with the excep-
tion of BP in which case the criterion used was according
to the North American Task Force guidelines [20]. There-
fore, MetS was diagnosed by abdominal obesity (WC ≥90th
percentile for child’s age, gender and ethnic origin) [23,24]
and the presence of two or more other clinical features:
triglycerides ≥150 mg/dL; HDL-C ≤40 mg/dL, BP sys-
tolic and/or diastolic ≥90th percentile for child’s age,
gender and height; fasting glucose ≥100 mg/dL.
Statistical analysis
Anthropometric and metabolic data were tested for nor-
mal distribution using skewness and kurtosis. Compari-
sons between continuous variables and groups were
performed with Student t test or Mann–Whitney U testTable 1 Anthropometric, clinical and metabolic characteristic
Characteristics Eutrophic Obese
n = 196 n = 190
Mean ± SD Mean ± SD
Age (years) 9.4 ± 1.8 9.6 ± 1.8
Anthropometric measurements
WC (cm) 57.8 ± 4.9 79.0 ± 9.1
BMI (kg/m2) 16.4 ± 1.3 24.5 ± 2.7
BMI percentilea 46.1 ± 18.2 97.4 ± 1.3
Blood pressure (mm/Hg)
SBP 88.6 ± 7.8 97.8 ± 8.8
SBP percentileb 17.3 ± 18.2 33.8 ± 22.9
Diastolic 55.8 ± 7.1 62.2 ± 7.6
DBP percentileb 37.7 ± 20.9 53.6 ± 21.5
Metabolic parameters*
Glucose (mg/dL) 90.0 (57.0-14.0) 90.0 (58.0-108.0)
Insulin (mU/mL) 4.3 (1.9-19.5) 9.3 (2.0-68.0)
HOMA-IRc 1.0 (0.3-5.0) 2.0 (0.4-13.9)
TGs (mg/dL) 72.0 (22.5-193.5) 106.5 (30.0-366.0)
HDL-C (mg/dL) 53.0 (21.0-110.0) 44.0 (9.0-82.0)
Inflammatory*
Adiponectin (μg/mL) 14.5 (3.9-38.8) 11.5 (1.4-27.5)
aAccording to CDC 2000.
bAccording to The National High Blood Pressure Education Program.
cHOMA-IR: [(fasting glucose (mg/dL))(fasting insulin (μU/mL))/ 405)].
d t test p value for means or Mann Whitney U test for medians: eutrophic vs. eutrop
*Median (min-max).
MetS, metabolic syndrome; WC, waist circumference; BMI, body mass index; SBP, sy
high-density lipoprotein cholesterol; MetS, metabolic syndrome.according to data distribution. In order to assess the
effect of adiponectin on each of the MetS components,
insulin and HOMA-IR, this hormone was categorized in
tertiles, and obese individuals were reclassified to those
with or without MetS. Differences in metabolic features
between adiponectin tertile categories were obtained
using linear regression analysis. The prevalence of each
component of MetS was obtained within each of the adi-
ponectin tertiles. To assess the odds of developing MetS,
these were compared in whole population according to
the previously mentioned adiponectin tertile categories
using logistic regression analysis and adjusted by BMI and
sex and age. P <0.05 was accepted as statistically signifi-
cant. Data were processed with STATA, SE v.11.0, and
EPIINFO 3.3.2 according to the 2000 CDC reference [19].
Results
Anthropometric features, blood pressure, metabolic pro-
file and adiponectin concentrations of eutrophic and
obese children with or without MetS are shown in
Table 1. Age range of the participants was 6–12 yearss in eutrophic and obese children with and without MetS
Obese
Without MetS With MetS
n = 166 n = 24
Pd Mean ± SD Mean ± SD Pe
0.368 9.6 ± 1.9 9.4 ± 1.4 0.623
<0.001 78.3 ± 9.2 83.5 ± 6.5 0.004
<0.001 24.3 ± 2.8 25.8 ± 2.5 0.009
<0.001 97.2 ± 1.3 98.3 ± 0.9 <0.001
<0.001 97.1 ± 8.2 101.3 ± 10.8 0.028
<0.001 32.0 ± 21.1 43.2 ± 30.6 0.037
<0.001 61.4 ± 7.2 65.9 ± 7.9 0.009
<0.001 51.7 ± 20.5 63.5 ± 22.3 0.021
0.794 90.0 (58.0-108.0) 94.0 (54.0-107.0) 0.090
<0.001 9.1 (2.0-55.2) 14.1 (3.8-68.0) <0.001
<0.001 2.0 (0.4-13.9) 3.5 (0.7-11.2) <0.001
<0.001 104.0 (30.0-366.0) 166.0 (72.9-255.0) <0.001
<0.001 45.0 (20.0-82.0) 36.0 (9.0-51.0) <0.001
<0.001 12.2 (1.4-27.5) 8.4 (4.2-15.3) 0.003
hic obese, eObese without MetS vs. obese with MetS.














































Figure 1 Prevalence of metabolic syndrome components by nutritional status. WC, waist circumference; SBP, systolic blood pressure; DBP,
diastolic blood pressure; TGs, triglycerides; HDL-C, high-density lipoprotein cholesterol.
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~13%. BMI was different between eutrophic and obese
participants and also between obese children with or
without MetS (P =0.004). BP (systolic and diastolic)
values and percentiles were different between eutrophic
and obese children (P <0.001) and also between children
with or without MetS (P <0.05).
In terms of metabolic variables, obese children with
MetS exhibited higher values of these variables than
obese children without MetS and eutrophic children.
Glucose values were not different between groups, but in-
sulin concentrations increased significantly in obese chil-
dren and especially in obese children with MetS (P <0.001).
HOMA-IR values within the obese group with MetS were
higher than those for the other groups (P <0.001). A similar

































Figure 2 Prevalence of metabolic syndrome components in obese ch
SBP, systolic blood pressure; DBP, diastolic blood pressure; TGs, triglyceridesAnother parameter that differed was HDL-C, in which
case the obese group with MetS showed the lowest
values (P <0.001). Adiponectin levels in eutrophic children
were higher compared with the obese group (P < 0.001).
Interestingly, lower concentrations of adiponectin were
observed in the obese with MetS compared with obese
without MetS (P =0.003).
Figures 1 and 2, show the prevalence of MetS and each
of its altered components, according to nutritional status
and adiponectin concentration. Figure 1 demonstrates
that none of the eutrophic children had MetS showing a
low prevalence in fasting glucose, HDL-C, and triglycer-
ide alterations. Likewise, none of them had altered waist
circumference and virtually no impairment in BP was
shown. In contrast, 13% of the obese children had MetS.
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ildren, according to adiponectin tertile. WC, waist circumference;
; HDL-C, high-density lipoprotein cholesterol.
Table 2 Insulin resistance and MetS components according to level of adiponectin, in eutrophic and obese children
and adolescents
Adiponectin tertile (values)
Eutrophic subjects (n = 196) Obese subjects (n = 190)
3 2 1 3 2 1
Outcome variables (17.6-38.8) (12.6-17.5) (3.9-12.5) (13.4-27.5) (9.6-13.3) (1.4-9.5)
Insulin resistance
Fasting insulin (μm/mL)
Coefficient Referent 0.9 1.1 Referent 3.3 3.4
95% CI - −0.1; 1.9 0.1; 2.1 - −0.1; 6.5 0.2; 6.7
P - 0.083 0.032 - 0.053 0.039
HOMA-IR
Coefficient Referent 0.2 0.3 Referent 0.6 0.8
95% CI - −0.1; 0.4 0.1; 0.5 - −0.2; 1.3 0.1; 1.6
P - 0.123 0.035 - 0.126 0.022
Components of MetS
WC (cm)
Coefficient Referent 0.9 3.1 Referent 4.9 5.9
95% CI - −0.6; 2.4 1.6; 4.6 - 2.1; 7.7 3.1; 8.7
P - 0.229 <0.001 - 0.001 <0.001
Blood pressure (mmHg)
SBP
Coefficient Referent 0.8 1.9 Referent 3.8 4.5
95% CI - −1.8; 3.5 −0.8; 4.5 - 0.9; 6.7 1.6; 7.3
P - 0.538 0.168 - 0.010 0.002
DBP
Coefficient Referent 1.6 2.5 Referent 1.7 0.9
95% CI - −0.9;4.0 0.1; 5.0 - −1.0; 4.3 −1.8; 3.5
P - 0.213 0.043 - 0.585 0.738
Glucose (mg/dL)
Coefficient Referent 0.1 0.5 Referent −0.4 3.9
95% CI - −3.6; 3.9 −3.2; 4.3 - −3.9; 3.1 −0.4; 7.4
P - 0.962 0.789 - 0.140 0.029
TGs (mg/dL)
Coefficient Referent −2.3 4.8 Referent 14.4 27.3
95% CI - −13.5; 8.9 −6.2; 15.9 - −8.0; 36.8 4.9; 49.6
P - 0.931 0.391 - 0.206 0.017
HDL-C (mg/dL)
Coefficient Referent 2.2 −0.3 Referent −1.3 −4.1
95% CI - −2.4; 6.8 −5.2; 4.5 - −5.3; 2.6 −8.1; 0.1
P - 0.351 0.894 - 0.511 0.048
Values obtained through linear regression and adjusted for gender and body mass index percentile.
Regression coefficients are change in outcome variables per tertile change in adiponectin concentration.
MetS, metabolic syndrome; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; TGs, triglycerides; HDL-C, high-density
lipoprotein cholesterol.
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Table 3 Odds ratio of developing MetS according to
adiponectin tertile value
Variable OR 95% CI P
Gender (female) 0.8 0.28; 2.46 0.737
Age (years) 0.8 0.57; 1.12 0.200
BMI (percentile) 2.0 1.20; 3.39 0.008
HOMA-IR 1.4 1.10; 1.73 0.006
Adiponectin tertile*
3 1 - -
2 4.8 0.84; 26.83 0.078
1 10.3 2.05; 48.16 0.005
Values obtained through logistic regression analysis, the final model included
whole study population (obese and eutrophic children) adjusted for BMI (body
mass index) percentile, gender, age and HOMA-IR values. *Tertiles used are
according to nutritional status of each child as shown in Table 2.
Klünder-Klünder et al. BMC Public Health 2013, 13:88 Page 6 of 8
http://www.biomedcentral.com/1471-2458/13/88waist circumference (50%), HDL-C (35%), triglycerides
(23%), and fasting glucose (15%). Children with altered
BP were very few in both groups.
Figure 2 shows that prevalence of MetS components
increase as adiponectin concentrations decrease in obese
children. When adiponectin values were in the first ter-
tile, 31% of these children had hypertrigliceridemia and
42% had low HDL-C values, compared to children in the
third tertile who presented 16% and 29%, respectively.
Table 2 shows a trend of increasing insulin and
HOMA-IR when adiponectin values decreased in eu-
trophic and obese children (p < 0.05). Also, in obese chil-
dren the appearance of the components of MetS was
higher when adiponectin values were in the low tertile
(P <0.05).
In obese children, WC and systolic BP increased when
adiponectin decreased to the second tertile (P = 0.001;
P =0.010). Additionally, when adiponectin decreased to
the low tertile, WC and systolic BP significantly
increased; 5.9 cm in WC (P <0.001), and 4.5 mmHg in
systolic blood pressure (P =0.002). Glucose increased
3.9 mg/dL (P =0.029). Triglycerides increased 27.3
mg/dL (P = 0.017), whereas HDL-C decreased 4.1 mg/dL
(P = 0.048).
Table 3 shows how the odds of developing MetS are
higher when adiponectin levels are lower (adjusted for
gender, age, BMI and HOMA-IR). When adiponectin is
in the first tertile, the odds ratio of developing MetS is
10.3 compared with the third tertile (95% CI 2.05;
48.16).
Discussion
Our study found that adiponectin levels are associated
with MetS as a whole and with each of its components,
mainly in obese children.
Considering the age of participants, some of them
could be in the pubertal stage, especially girls who can
enter this phase up to two years earlier than boys [25].
Unfortunately, the pubertal stage was not measured in
the study, and we cannot discriminate the potential in-
fluence of sexual hormones on changes in adiponectin.
However, in studies in which the pubertal stage has been
controlled, results regarding the association between adi-
ponectin and MetS are controversial. Some of them
show that pubertal stage mediates the association be-
tween adiponectin and MetS [26,27], while others per-
formed in Latin-American children did not find this
observation [14,28]. In the present study, adiponectin
concentration between boys and girls were similar with
values of 12.8 and 13.3 μg/mL, respectively (p = 0.362).
Concerning the prevalence of 13% of MetS in obese
children reported herein, and in order to properly locate
this figure in relationship to others, we compared this
prevalence with other studies in which the IDFdefinition was applied. In doing so, we found that the
prevalence of MetS in obese children has a wide vari-
ation; in Greek children is 7.7%, in Colombian is 11.7%
[27,29], in Chinese and Spanish obese children is 27.6
and 19.6% respectively [30,31], and in another study on
Mexican obese children the prevalence was 20% [32].
Notwithstanding the same IDF definition of MetS, vari-
ation could be explained by the differences in the envir-
onment in which the children live.
It is noteworthy that independent of nutritional status
of the children, when their adiponectin levels are in the
lowest tertile all the components of MetS worsen; WC,
diastolic BP, glucose, and triglycerides increase and
HDL-C values decrease. On the other hand, when adipo-
nectin levels are in the high tertiles, each component of
MetS improves even in obese children, although it is not
possible to say that these individuals are metabolically
healthy.
A similar phenomenon but with less magnitude is
observed in eutrophic children. Nowadays, we do not
have a plausible way of explaining why adiponectin in
eutrophic children decreases because they are not
exposed to the inflammatory environment of obesity;
however, eutrophic children with adiponectin concentra-
tions in the low tertile have significantly higher values of
HOMA IR, WC and diastolic BP than those in the high
tertile. To our knowledge, the present work is the first
to show that adiponectin also influences metabolic
changes in eutrophic children, even after adjustment of
adiponectin levels by BMI and gender.
In a recent bariatric surgery study that was made up of
morbidly obese patients, the association between adipo-
nectin genes and adiponectin expression was studied in
eight patients with T2D and four control patients [33].
Adiponectin production was downregulated in obese
patients but upregulated once obesity was reduced. Its
production rose to levels close to the control group,
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with obesity. The versatile replenishment of this adipo-
kine with weight loss supports the importance of using
this cytokine as a biomarker in prevention programs as
well as in treatment and control of diseases, especially
T2D.
Although there are reports in which adiponectin has
not been shown to be a useful biomarker for monitoring
changes observed in MetS [16,17], evidence exists for
postulating this cytokine as a biomarker of MetS and
T2D in obese children and adolescents [13,14,34,35].
However, the molecular mechanisms that establish the re-
lationship between adiponectin and metabolic derange-
ments observed in clinical and epidemiological studies,
have not been fully elucidated [36]. The most plausible ex-
planation is that obesity, mainly visceral, is a condition in
which there is an inflammatory state characterized by
dysregulated production of adipokines in which anti-
inflammatory agents such as adiponectin decrease while
pro-inflammatory cytokines such TNFα and IL-6, IL 1β
increase. Unfortunately pro- inflammatory cytokines were
not measured in order to demonstrate their predomin-
ance, although at present, there is practically no discussion
about the negative association between central obesity and
adiponectin levels [37,38].
The use of adiponectin as a marker for MetS has
already been shown in a 3-year prospective study where
adiponectin levels in Korean children predicted the de-
velopment of the MetS [26].
In addition to aforementioned limitations, it is neces-
sary to highlight that this study is cross-sectional in de-
sign, which only permits associations but not causality
to be established among different variables. Lastly, because
the study was performed in an ethnically homogenous
population in Mexico City its results may not apply to
other populations. Despite these limitations, the negative
association between adiponectin and the components of
MetS suggest that these children have an imbalance in in-
flammatory adipokines.
Conclusion
In this sample of eutrophic and obese Mexican children,
an inversely proportional relationship was found be-
tween adiponectin concentrations and MetS compo-
nents, which supports the idea that this hormone could
be a possible biomarker to identify individuals with risk
of developing MetS.
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